KDJ05002
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Long term use of lokivetmab (Cytopoint®) in atopic dogs., PMID:40133889
Long-term use of lokivetmab in dogs with atopic dermatitis., PMID:39143659
Efficacy of verdinexor for the treatment of naïve canine epitheliotropic cutaneous T-cell lymphoma: An open-label pilot study., PMID:39074816
Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine., PMID:38932349
Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab., PMID:37389418
Cutaneous mastocytosis in 8 young dogs and review of literature., PMID:37222130
Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study., PMID:37186491
Hair cortisol concentration, disease severity and quality of life in dogs with atopic dermatitis during lokivetmab therapy., PMID:37165693
Cytokine transcriptome profiling in acute experimental canine atopic dermatitis skin lesions after IL-31 inhibition with lokivetmab., PMID:37006124
Laboratory safety evaluation of lokivetmab, a canine anti-interleukin-31 monoclonal antibody, in dogs., PMID:36842258
Use of Cytopoint in the Allergic Dog., PMID:35928119
What can we learn from treating atopic itch in dogs?, PMID:35609710
Clinical Guidelines for the Use of Antipruritic Drugs in the Control of the Most Frequent Pruritic Skin Diseases in Dogs., PMID:35448647
Lokivetmab improved pruritus in a dog with cutaneous epitheliotropic lymphoma., PMID:34866072
Local and Systemic Changes in Lipid Profile as Potential Biomarkers for Canine Atopic Dermatitis., PMID:34677385
In vitro evaluation of potential interference of lokivetmab with protein electrophoresis and immunofixation., PMID:34425606
Weekly topical therapy based on plant extracts combined with lokivetmab in canine atopic dermatitis., PMID:34414621
A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis., PMID:34180084
Multivariable analysis of the influence of cross-reactive carbohydrate determinant inhibition and other factors on intradermal and serological allergen test results: a prospective, multicentre study., PMID:34105194
Onset and duration of action of lokivetmab in a canine model of IL-31 induced pruritus., PMID:33830571
Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment., PMID:33559859
Evaluation of the clinical efficiency of lokivetmab in client privately owned atopic dogs - multicenter study., PMID:32627992
Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs., PMID:32301565
The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis., PMID:31090122
Proactive maintenance therapy of canine atopic dermatitis with the anti-IL-31 lokivetmab. Can a monoclonal antibody blocking a single cytokine prevent allergy flares?, PMID:30672050
Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis., PMID:30479052
Atopic dermatitis in cats and dogs: a difficult disease for animals and owners., PMID:30323921
An embarrassment of riches: An update on the symptomatic treatment of canine atopic dermatitis., PMID:30197448
A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA., PMID:30141223
[New drugs for small animals in 2017]., PMID:29727897
A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis., PMID:28906040
A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis., PMID:27647569
A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis., PMID:27647513
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
